Erasca, Inc. Overview
Pro stress-test →Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The RAS/MAPK pathway is linked to approximately 5.5 million new cases of cancer per year worldwide, over 90% of which have limited or no treatment options. Erasca is advancing a pipeline of oral targeted therapies designed to address this massive unmet medical need.
Strategic Profile
Pro stress-test →The company's strategy combines a pan-RAS molecular glue and a pan-KRAS inhibitor, giving exposure to different "swim lanes" that could emerge across tumor types and treatment settings. With a strong cash position of $411 million as of March 31, 2025, the company has operational funding through the second half of 2028. In January 2026, Erasca completed an upsized public offering of 25,875,000 shares, raising $225 million, further strengthening its financial runway.
Competitive Landscape
Pro stress-test →Erasca has strategic partnerships with Novartis (naporafenib co-development), Katmai Pharmaceuticals (ERAS-801), and NiKang Therapeutics (ERAS-601). The molecular glue space is competitive, with RevMed's RMC-6236 as a benchmark program. Erasca's ERAS-0015 demonstrates superior binding affinity and dosing advantages versus RMC-6236 preclinically.
Industry Context
Erasca, Inc. operates in Precision Oncology / Biopharmaceuticals - RAS/MAPK Pathway Targeting.
Key facts
Founded: 2018 · Headquarters: San Diego, California · Revenue: $0